Skip to Content
Merck
  • Outcomes of pancreas retransplantation after simultaneous kidney-pancreas transplantation are comparable to pancreas after kidney transplantation alone.

Outcomes of pancreas retransplantation after simultaneous kidney-pancreas transplantation are comparable to pancreas after kidney transplantation alone.

Transplantation (2014-08-26)
John Seal, Markus Selzner, Jerome Laurence, Max Marquez, Fateh Bazerbachi, Ian McGilvray, Jeffrey Schiff, Andrea Norgate, Mark S Cattral
ABSTRACT

There is a paucity of contemporary data describing the results of pancreas retransplantation (PRT). As a measure of utility, we wished to determine whether PRT could produce equivalent short-term and long-term recipient outcomes to primary pancreas after kidney (PAK) transplantation. Retrospective analysis of 96 consecutive pancreas only transplants performed from 2003 to May 2012. Primary PAK transplants (n = 78) were compared to PRT (n=18). Donor and recipient demographics were similar. Pancreas graft survival was similar for PAK and PRT at 1 year (88.2% vs. 100%) and 3 years (85.1% vs. 85.1%). Pancreas graft failure occurred in 14 PAK and two PRT patients with a mean follow-up of 61.6 ± 38.7 and 37.8 ± 26.1 months, respectively. There were no differences in postoperative length of stay (9.9 days vs. 8.7 days; P = 0.9) or postoperative complications in the first 3 months (47.4% vs. 38.9%, P = 0.6). At 3-year follow-up, both groups had comparable HBA1c (0.06 vs. 0.05; P = 0.8), serum creatinine (116.6 μmol/L v 131.7 μmol/L; P = 0.09), and oral glucose tolerance tests. Pancreas retransplantation is a safe and effective therapy for select recipients after graft loss. Pancreas retransplantation is associated with the same risk of postoperative complications and has similar intermediate-term graft survival compared to primary PAK transplantation.

MATERIALS
Product Number
Brand
Product Description

Mycophenolate mofetil for peak identification, European Pharmacopoeia (EP) Reference Standard
Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Mycophenolate mofetil, ≥98% (HPLC)
Supelco
Mycophenolate Mofetil, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Mycophenolate mofetil, United States Pharmacopeia (USP) Reference Standard